These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 7749136)

  • 21. Clinical significance of circulating tumor cells (CTCs) with respect to optimal cut-off value and tumor markers in advanced/metastatic breast cancer.
    Shiomi-Mouri Y; Kousaka J; Ando T; Tetsuka R; Nakano S; Yoshida M; Fujii K; Akizuki M; Imai T; Fukutomi T; Kobayashi K
    Breast Cancer; 2016 Jan; 23(1):120-127. PubMed ID: 24906662
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Is parathyroid hormone-related protein a sensitive serum marker in advanced breast cancer?
    Pyke CM; Menezes G; Purdie DM; Johnson S; Cowley D
    Aust N Z J Surg; 1997 May; 67(5):256-9. PubMed ID: 9152154
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinicopathological and Prognostic Significance of Cancer Antigen 15-3 and Carcinoembryonic Antigen in Breast Cancer: A Meta-Analysis including 12,993 Patients.
    Li X; Dai D; Chen B; Tang H; Xie X; Wei W
    Dis Markers; 2018; 2018():9863092. PubMed ID: 29854028
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of bone scintigraphy with serum tumor markers of CA 15-3 and carcinoembryonic antigen in patients with breast carcinoma.
    Gedik GK; Kiratli PO; Tascioglu B; Aras T
    Saudi Med J; 2006 Mar; 27(3):317-22. PubMed ID: 16532090
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of tumor markers in southern Indian breast cancer patients.
    Porika M; Malotu N; Veldandi UK; Yadala N; Abbagani S
    Asian Pac J Cancer Prev; 2010; 11(1):157-9. PubMed ID: 20593949
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Development and verification of a prediction model using serum tumor markers to predict the response to chemotherapy of patients with metastatic or recurrent breast cancer.
    Yonemori K; Katsumata N; Noda A; Uno H; Yunokawa M; Nakano E; Kouno T; Shimizu C; Ando M; Tamura K; Takeuchi M; Fujiwara Y
    J Cancer Res Clin Oncol; 2008 Nov; 134(11):1199-206. PubMed ID: 18528707
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Diagnostic Value of Serum Concentration and Integrity of Circulating Cell-Free DNA in Breast Cancer: A Comparative Study With CEA and CA15-3.
    Tang Z; Li L; Shen L; Shen X; Ju S; Cong H
    Lab Med; 2018 Oct; 49(4):323-328. PubMed ID: 29701836
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Circulating tumor DNA in Egyptian women with breast Cancer: A marker for detection of primary cases and early prediction of recurrence.
    Gameel AM; Talaat RM; Sakr MA; Selim MA; Abo Alil DFA; Elkhouly EA
    Clin Chim Acta; 2024 Aug; 562():119878. PubMed ID: 39047884
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Serum and immunohistochemical studies of NCC-ST-439 in breast cancer.
    Narita T; Funahashi H; Satoh Y; Imai T; Takagi H
    J Surg Oncol; 1993 Sep; 54(1):5-8. PubMed ID: 8377506
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Elevated levels of serum tumor markers CA 15-3 and CEA are prognostic factors for diagnosis of metastatic breast cancers.
    Lee JS; Park S; Park JM; Cho JH; Kim SI; Park BW
    Breast Cancer Res Treat; 2013 Oct; 141(3):477-84. PubMed ID: 24072270
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of serum CA15-3 determination with CEA and TPA in the post-operative follow-up of breast cancer patients.
    Nicolini A; Colombini C; Luciani L; Carpi A; Giuliani L
    Br J Cancer; 1991 Jul; 64(1):154-8. PubMed ID: 1854615
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High levels of serum CA15-3 and residual invasive tumor size are associated with poor prognosis for breast cancer patients with non-pathological complete response after neoadjuvant chemotherapy.
    Fujimoto Y; Higuchi T; Nishimukai A; Miyagawa Y; Kira A; Ozawa H; Bun A; Imamura M; Miyoshi Y
    J Surg Oncol; 2018 Jul; 118(1):228-237. PubMed ID: 29936704
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Concordance of Hypermethylated DNA and the Tumor Markers CA 15-3, CEA, and TPA in Serum during Monitoring of Patients with Advanced Breast Cancer.
    Kristiansen S; Jørgensen LM; Hansen MH; Nielsen D; Sölétormos G
    Biomed Res Int; 2015; 2015():986024. PubMed ID: 26339655
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The evaluation of combined scintimammography and tumor markers in breast cancer patients.
    Mangkharak J; Patanachak C; Podhisuwan K; Pleehachinda R
    Anticancer Res; 1997; 17(3B):1611-4. PubMed ID: 9179203
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Utility of CA 15-3 and CEA in monitoring breast cancer patients with bone metastases: special emphasis on "spiking" phenomena.
    Yasasever V; Dinçer M; Camlica H; Karaloğlu D; Dalay N
    Clin Biochem; 1997 Feb; 30(1):53-6. PubMed ID: 9056110
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Serum c-erbB-2 protein is a useful marker for monitoring tumor recurrence of the breast.
    Imoto S; Wada N; Hasebe T; Ochiai A; Kitoh T
    Int J Cancer; 2007 Jan; 120(2):357-61. PubMed ID: 17044019
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tumor-associated glycoprotein-72 serum levels complement carcinoembryonic antigen levels in monitoring patients with gastrointestinal carcinoma. A longitudinal study.
    Guadagni F; Roselli M; Amato T; Cosimelli M; Mannella E; Perri P; Abbolito MR; Cavaliere R; Colcher D; Greiner JW
    Cancer; 1991 Dec; 68(11):2443-50. PubMed ID: 1933781
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Relationship between bone scintigraphy and tumor markers in patients with breast cancer.
    Yildiz M; Oral B; Bozkurt M; Cobaner A
    Ann Nucl Med; 2004 Sep; 18(6):501-5. PubMed ID: 15515750
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Diagnostic efficacy of CA 15-3 and CEA in the early detection of metastatic breast cancer-A retrospective analysis of kinetics on 743 breast cancer patients.
    Stieber P; Nagel D; Blankenburg I; Heinemann V; Untch M; Bauerfeind I; Di Gioia D
    Clin Chim Acta; 2015 Aug; 448():228-31. PubMed ID: 26160053
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mammary serum antigen (MSA), Ca 549, CA 15-3 and CEA in breast cancer preoperative sensitivity and correlation to prognostic factors.
    Heinze T; Schürenkämper P; Minguillon C; Lichtenegger W
    Anticancer Res; 1997; 17(4B):2953-4. PubMed ID: 9329573
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.